Kezar Life Sciences Inc
2KZ0
Company Profile
Business description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Contact
4000 Shoreline Court
Suite 300
South San FranciscoCA94080
USAT: +1 650 822-5600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
55
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,910.40 | 19.50 | -0.22% |
| CAC 40 | 8,124.88 | 56.26 | 0.70% |
| DAX 40 | 24,229.91 | 43.42 | 0.18% |
| Dow JONES (US) | 48,416.56 | 41.49 | -0.09% |
| FTSE 100 | 9,751.31 | 102.28 | 1.06% |
| HKSE | 25,349.05 | 279.83 | -1.09% |
| NASDAQ | 23,057.41 | 137.76 | -0.59% |
| Nikkei 225 | 49,515.14 | 652.97 | -1.30% |
| NZX 50 Index | 13,425.81 | 17.67 | 0.13% |
| S&P 500 | 6,816.51 | 10.90 | -0.16% |
| S&P/ASX 200 | 8,628.20 | 19.10 | -0.22% |
| SSE Composite Index | 3,835.71 | 32.21 | -0.83% |